Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma.

13 Jun 2013

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Before we talk about p53, it is important to understand why cancer cells are a problem for the body. Cancer cells multiply recklessly, refuse to die and blithely metastasize to set up shop in places where they don’t belong.

12 Jun 2013

Researchers find master regulator of EMT and metastasis

The predominant cause of death in cancer patients is metastasis, the formation of secondary tumors in other organs like the brain, liver, and lungs. Cancer cells detach from the original primary tumor and reach a single cell or group of cells in another organ. The cells of the body normally remain in place through adhering to an extracellular substance. However, cancer cells learn how to release themselves from these bonds and invade surrounding tissues, blood, and the lymphatic system.

11 Jun 2013

New non-invasive test measures methylation of SDC2 gene, detects 87% of colorectal cancer

The average 5-year survival for colorectal cancer (CRC) is less than 10% if metastasis occurs, but can reach 90% if detected early. A new non-invasive test has been developed that measures methylation of the SDC2 gene in tissues and blood sera.

10 Jun 2013

Cancer Institute of New Jersey offers COMET-2 clinical trial to examine cabozantinib drug

The Cancer Institute of New Jersey is one of 50 sites across the nation to offer a clinical trial known as COMET-2 that examines whether the drug cabozantinib is effective in reducing bone pain in patients with prostate cancer that is no longer responsive to hormone therapy and has spread (metastasized) to other parts of the body.

7 Jun 2013

Molecular subtyping can predict chemotherapy benefit in patients with colorectal cancer

Molecular subtyping can help predict outcomes and chemotherapy benefit in patients with colorectal cancer, according to a presentation at the annual conference of the American Society of Clinical Oncology (ASCO).

6 Jun 2013

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

BioLineRx, a biopharmaceutical development company, announced today enrollment of the first patient in a Phase 2 trial for BL-8040, for the treatment of acute myeloid leukemia.

6 Jun 2013

Scientists develop first dual-action drug against melanoma skin cancer cells

Scientists are reporting development and successful lab tests on the first potential drug to pack a lethal one-two punch against melanoma skin cancer cells. Hit number one destroys cells in the main tumor, and the second hit blocks the spread of the cancer to other sites in the body, according to their report in the journal ACS Chemical Biology.

6 Jun 2013

Researchers to receive ASTRO Gold Medal for outstanding contributions to the field of radiation oncology

The American Society for Radiation Oncology (ASTRO) will award Amato J. Giaccia, PhD, Radhe Mohan, PhD, FASTRO, and Prabhakar Tripuraneni, MD, FASTRO, with the Society's highest honor—the ASTRO Gold Medal. The 2013 awardees will receive the ASTRO Gold Medal during the Awards Ceremony on Tuesday, September 24, at ASTRO's 55th Annual Meeting, September 22-25, 2013, at the Georgia World Congress Center in Atlanta.

5 Jun 2013

Researchers demonstrate how modified citrus pectin works against cancer

A new review by researchers at the University of Maryland School of Medicine highlights a large body of published research demonstrating how modified citrus pectin, works against cancer.

4 Jun 2013

Researchers solve long-standing mystery behind dormant disseminated breast tumor cells

The long-standing mystery behind dormant disseminated breast tumor cells and what activates them after years and even decades of latency may have been solved. Researchers with the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory (Berkeley Lab) have identified the microenvironment surrounding microvasculature - the small blood vessels that transport blood within tissues - as a niche where dormant cancer cells reside. When these blood vessels begin to sprout, the new tips produce molecules that transform dormant cancer cells into metastatic tumors.

4 Jun 2013

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.

4 Jun 2013

Aaxillary lymph node dissection and radiotherapy provide excellent regional control for patients with breast cancer

Final analysis of the EORTC 10981-22023 AMAROS (After Mapping of the Axilla: Radiotherapy Or Surgery?) trial has shown that both axillary lymph node dissection and axillary radiotherapy provide excellent regional control for breast cancer patients with a positive sentinel node biopsy

3 Jun 2013

NewLink Genetics announces results from two clinical studies with indoximod

NewLink Genetics Corporation, an oncology-focused biopharmaceutical company specializing in immunotherapy, today announced results from two clinical studies with indoximod, an orally administered small molecule drug candidate that inhibits the IDO pathway.

3 Jun 2013

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and molecular diagnostic products, today announced new results from the combined data analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Arimidex, Tamoxifen, Alone or in Combination studies.

From NanoString Technologies 3 Jun 2013

Five studies on breast, colon and colorectal cancer to be presented at ASCO Annual Meeting

Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology Annual Meeting to be held May 31-June 4, 2013 at McCormick Place in Chicago.

1 Jun 2013

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.

31 May 2013

Isaiah J. Fidler earns 2013 American Cancer Society Medal of Honor for Basic Research

When Isaiah J. Fidler, D.V.M., Ph.D., left his veterinary surgical practice to pursue a doctorate that would allow him to study and combat the lethal spread of cancer to other organs, he got lots of advice. The common message: Don't go there.

30 May 2013

Scientists find that 'junk DNA' could promote cancer progression

Scientists at The University of Nottingham have found that a genetic rogue element produced by sequences until recently considered 'junk DNA' could promote cancer progression.

30 May 2013

Metastasis News and Research

Further Reading

PRISM Pharma announces closing of $15 million Series C financing

Verastem's VS-6063 gets orphan drug designation from European Commission for use in mesothelioma

Tumor suppressor p53 inactivation and restoration: an interview with Dr. Xin Lu, Ludwig Institute for Cancer Research

Researchers find master regulator of EMT and metastasis

New non-invasive test measures methylation of SDC2 gene, detects 87% of colorectal cancer

Cancer Institute of New Jersey offers COMET-2 clinical trial to examine cabozantinib drug

Molecular subtyping can predict chemotherapy benefit in patients with colorectal cancer

BioLineRx starts enrollment in Phase 2 trial of BL-8040 for treatment of AML

Scientists develop first dual-action drug against melanoma skin cancer cells

Researchers to receive ASTRO Gold Medal for outstanding contributions to the field of radiation oncology

Researchers demonstrate how modified citrus pectin works against cancer

Researchers solve long-standing mystery behind dormant disseminated breast tumor cells

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

Aaxillary lymph node dissection and radiotherapy provide excellent regional control for patients with breast cancer

NewLink Genetics announces results from two clinical studies with indoximod

NanoString's Prosigna Breast Cancer Assay can help identify node-positive early-stage breast cancer

Five studies on breast, colon and colorectal cancer to be presented at ASCO Annual Meeting

Exelixis starts phase 3 pivotal trial of cabozantinib for treatment of metastatic renal cell carcinoma

Isaiah J. Fidler earns 2013 American Cancer Society Medal of Honor for Basic Research

Scientists find that 'junk DNA' could promote cancer progression

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News